In contrast to the target specificity paradigm, a dominant concept in drug discovery, multi-targeting protein kinase inhibitors could simultaneously affect different nodes within a kinase signaling network and more effectively eliminate therapy-resistance tumor cells [83]. Here, WEE1 is linked to neoplasm.